President and CFO Andrew Guggenhime reported the disposition of 2,705 shares of Vaxcyte, Inc. (NASDAQ:PCVX), according to a recent SEC Form 4 filing. Post-transaction shares (indirectly held) Transaction value based on SEC Form 4 weighted average sale price ($61.18); post-transaction value based on the September 2 market close ($61.58). What was the specific nature of this disposition?The transaction involved 2,705 shares that were surrendered directly to the company to satisfy tax withholding obligations.
This occurred automatically upon the vesting of restricted stock units and was not a discretionary open-market sale. How is the insider's total equity structured?Guggenhime retains about 164,000 shares of Vaxcyte, consisting of 102,000 shares held directly and 61,850 shares held indirectly via ALG 2025 Grat Holdings LLC. The total position was valued at $10.12 million based on the September 2 market close.
What is the recent performance context for the security?Vaxcyte shares have seen a 95% return over the one-year period ending September 2. This performance context coincides with the ongoing clinical development of the company's experimental vaccine candidates, including VAX-24. Share Price (as of market close 2026-09-01) Vaxcyte is a clinical-stage biotechnology company focused on developing innovative protein-based vaccines to prevent and manage bacterial infectious diseases, with its lead candidate VAX-24, a 24-valent pneumococcal conjugate vaccine currently in clinical trials.
The company operates a development-stage business model centered on advancing proprietary vaccine candidates through clinical trials with the objective of eventual commercialization and licensing partnerships with established pharmaceutical entities. Vaxcyte's primary target markets include healthcare systems, public health agencies, and pharmaceutical partners seeking next-generation vaccines to address unmet medical needs in infectious disease prevention, particularly in immunocompromised and elderly populations. Vaxcyte, Inc. is a clinical-stage biotechnology enterprise headquartered in San Carlos with 507 employees, focused on developing next-generation protein-based vaccines addressing significant gaps in infectious disease prevention.
The company's strategic approach leverages advanced conjugate vaccine technology to create multi-valent formulations with enhanced immunogenicity and broader pathogen coverage compared to existing therapeutic options. With a market capitalization of $9.0 billion and a one-year share price appreciation of 95.12%, Vaxcyte represents investor confidence in its clinical pipeline and the substantial market opportunity within the global vaccine sector. Guggenhime handed 2,705 shares back to Vaxcyte to settle taxes on vested restricted stock, roughly 1.6% of the 164,000 shares he holds directly and through a family entity.
More importantly, he carries the president and CFO titles at a company with no revenue, which makes the financing question his to answer.On that front, Vaxcyte held $2.51 billion in cash and investments at the end of June, up slightly from $2.44 billion at the end of last year, and Guggenhime said in the August 5 release that the balance sheet leaves the company "well positioned to execute" on clinical, manufacturing and commercial-readiness milestones, as spending climbs to meet those milestones. Operating expenses reached $302.8 million in the second quarter against $226.2 million a year earlier, and the six-month net loss came to $604.9 million.Some of that spending funds manufacturing for a commercial launch that requires trial data Vaxcyte doesn't have yet, but good results potentially coming in the fourth quarter make the buildout look prescient. Anything short of that leaves the company having pre-paid for a product it can't yet sell, with more readouts to get through before it can even file.
Extract — continue reading at the source.
